Lincoln Pharmaceuticals Ltd's Q3FY25 Quarter Results
- 14 Feb 2025
Result Summary
- Lincoln Pharmaceuticals Ltd reported a 9.2% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a decline of 1.2%.
- Its expenses for the quarter were down by 7.0% QoQ and up 5.9% YoY.
- The net profit decreased 21.1% QoQ and decreased 25.9% YoY.
- The earnings per share (EPS) of Lincoln Pharmaceuticals Ltd stood at 10.4 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 155.52 | 171.19 | 157.47 | -9.2% | -1.2% |
Total Expenses | 126.84 | 136.40 | 119.75 | -7.0% | 5.9% |
Profit Before Tax | 28.68 | 34.78 | 37.71 | -17.5% | -23.9% |
Tax | 7.91 | 8.45 | 9.67 | -6.4% | -18.2% |
Profit After Tax | 20.77 | 26.33 | 28.04 | -21.1% | -25.9% |
Earnings Per Share | 10.40 | 13.20 | 14.00 | -21.2% | -25.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Lincoln Pharmaceuticals Ltd is a company involved in the pharmaceutical industry. The company primarily focuses on the production and distribution of pharmaceutical products and formulations. It serves various therapeutic segments and offers a range of healthcare solutions. As a part of the pharmaceutical sector, Lincoln Pharmaceuticals Ltd operates in a regulated market, adhering to strict standards to ensure the efficacy and safety of its products. Information regarding any recent major developments or strategic initiatives taken by the company is not available.
Revenue
In the third quarter of FY25, Lincoln Pharmaceuticals Ltd reported a total income of ₹155.52 crores, showing a decrease of 9.2% compared to the previous quarter (Q2FY25) where the total income was ₹171.19 crores. Year-over-year, the total income decreased slightly by 1.2% from ₹157.47 crores in Q3FY24. This indicates a downward trend in revenue over both the quarterly and yearly periods. The decline in total income could be attributed to several factors, including market dynamics or changes in sales volume, but specific reasons are not detailed in the provided data.
Profitability
Profitability metrics for Lincoln Pharmaceuticals Ltd in Q3FY25 include a profit before tax (PBT) of ₹28.68 crores. This represents a decline of 17.5% from the previous quarter's PBT of ₹34.78 crores. Compared to the same quarter in the previous fiscal year (Q3FY24), PBT decreased by 23.9% from ₹37.71 crores. The tax expense for Q3FY25 was ₹7.91 crores, down 6.4% from Q2FY25 and down 18.2% YoY. Consequently, the profit after tax (PAT) was ₹20.77 crores, marking a significant decrease of 21.1% QoQ and 25.9% YoY. The decline in profitability across these periods is also reflected in the earnings per share (EPS), which stood at ₹10.40 in Q3FY25, declining from ₹13.20 in Q2FY25 and ₹14.00 in Q3FY24.
Operating Metrics
The operating expenses for Lincoln Pharmaceuticals Ltd in Q3FY25 totaled ₹126.84 crores, which is a decrease of 7.0% from the previous quarter's expenses of ₹136.40 crores. Year-over-year, there has been an increase of 5.9% from ₹119.75 crores in Q3FY24. Despite the reduced expenses quarter-over-quarter, the increase in expenses year-over-year suggests changes in operational costs, which could be due to inflationary pressures, increased production costs, or other operational factors. However, specific reasons for the changes in operating expenses are not provided in the data.
